CYTK
Price
$48.71
Change
+$0.88 (+1.84%)
Updated
Sep 26, 01:03 PM (EDT)
Capitalization
5.72B
34 days until earnings call
NGENF
Price
$2.43
Change
-$0.11 (-4.33%)
Updated
Sep 25 closing price
Capitalization
180.01M
Interact to see
Advertisement

CYTK vs NGENF

Header iconCYTK vs NGENF Comparison
Open Charts CYTK vs NGENFBanner chart's image
Cytokinetics
Price$48.71
Change+$0.88 (+1.84%)
Volume$200
Capitalization5.72B
NervGen Pharma
Price$2.43
Change-$0.11 (-4.33%)
Volume$43.41K
Capitalization180.01M
CYTK vs NGENF Comparison Chart in %
Loading...
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NGENF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CYTK vs. NGENF commentary
Sep 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYTK is a Buy and NGENF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 26, 2025
Stock price -- (CYTK: $47.83 vs. NGENF: $2.43)
Brand notoriety: CYTK and NGENF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYTK: 72% vs. NGENF: 58%
Market capitalization -- CYTK: $5.72B vs. NGENF: $180.01M
CYTK [@Biotechnology] is valued at $5.72B. NGENF’s [@Biotechnology] market capitalization is $180.01M. The market cap for tickers in the [@Biotechnology] industry ranges from $97.91B to $0. The average market capitalization across the [@Biotechnology] industry is $1.9B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYTK’s FA Score shows that 1 FA rating(s) are green whileNGENF’s FA Score has 0 green FA rating(s).

  • CYTK’s FA Score: 1 green, 4 red.
  • NGENF’s FA Score: 0 green, 5 red.
According to our system of comparison, CYTK is a better buy in the long-term than NGENF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYTK’s TA Score shows that 5 TA indicator(s) are bullish while NGENF’s TA Score has 5 bullish TA indicator(s).

  • CYTK’s TA Score: 5 bullish, 5 bearish.
  • NGENF’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, NGENF is a better buy in the short-term than CYTK.

Price Growth

CYTK (@Biotechnology) experienced а -2.96% price change this week, while NGENF (@Biotechnology) price change was -7.60% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.01%. For the same industry, the average monthly price growth was +9.06%, and the average quarterly price growth was +48.80%.

Reported Earning Dates

CYTK is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+1.01% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CYTK($5.72B) has a higher market cap than NGENF($180M). NGENF YTD gains are higher at: 11.468 vs. CYTK (1.679). NGENF has higher annual earnings (EBITDA): -26.41M vs. CYTK (-504.83M). CYTK has more cash in the bank: 858M vs. NGENF (15.7M). NGENF has less debt than CYTK: NGENF (57.7K) vs CYTK (858M). CYTK has higher revenues than NGENF: CYTK (85.7M) vs NGENF (0).
CYTKNGENFCYTK / NGENF
Capitalization5.72B180M3,179%
EBITDA-504.83M-26.41M1,912%
Gain YTD1.67911.46815%
P/E RatioN/AN/A-
Revenue85.7M0-
Total Cash858M15.7M5,465%
Total Debt858M57.7K1,487,002%
FUNDAMENTALS RATINGS
CYTK vs NGENF: Fundamental Ratings
CYTK
NGENF
OUTLOOK RATING
1..100
7657
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
96
Overvalued
PROFIT vs RISK RATING
1..100
7669
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4150
P/E GROWTH RATING
1..100
1100
SEASONALITY SCORE
1..100
7550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NGENF's Valuation (96) in the null industry is in the same range as CYTK (100) in the Biotechnology industry. This means that NGENF’s stock grew similarly to CYTK’s over the last 12 months.

NGENF's Profit vs Risk Rating (69) in the null industry is in the same range as CYTK (76) in the Biotechnology industry. This means that NGENF’s stock grew similarly to CYTK’s over the last 12 months.

NGENF's SMR Rating (100) in the null industry is in the same range as CYTK (100) in the Biotechnology industry. This means that NGENF’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's Price Growth Rating (41) in the Biotechnology industry is in the same range as NGENF (50) in the null industry. This means that CYTK’s stock grew similarly to NGENF’s over the last 12 months.

CYTK's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for NGENF (100) in the null industry. This means that CYTK’s stock grew significantly faster than NGENF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYTKNGENF
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 4 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
88%
Momentum
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 1 day ago
74%
MACD
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
81%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 16 days ago
78%
N/A
Declines
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
81%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
81%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NGENF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IFTAX12.26N/A
N/A
Voya International High Div Low Vol A
OSMYX42.29N/A
N/A
Invesco International Small-Mid Com Y
SECUX38.48N/A
N/A
NAA Mid Growth A
BIVRX17.12N/A
N/A
Invenomic Investor
SFCWX76.14-0.79
-1.03%
American Funds SMALLCAP World F3

CYTK and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYTK has been loosely correlated with IONS. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if CYTK jumps, then IONS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYTK
1D Price
Change %
CYTK100%
-0.95%
IONS - CYTK
63%
Loosely correlated
-1.52%
MLYS - CYTK
53%
Loosely correlated
-0.93%
NEVPF - CYTK
45%
Loosely correlated
N/A
ARWR - CYTK
45%
Loosely correlated
-3.56%
IMVT - CYTK
44%
Loosely correlated
+1.36%
More

NGENF and

Correlation & Price change

A.I.dvisor tells us that NGENF and CYTK have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NGENF and CYTK's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NGENF
1D Price
Change %
NGENF100%
-4.33%
CYTK - NGENF
25%
Poorly correlated
-0.95%
IBRX - NGENF
23%
Poorly correlated
-1.60%
CARM - NGENF
22%
Poorly correlated
-4.61%
ATRA - NGENF
22%
Poorly correlated
-3.02%
SGMO - NGENF
21%
Poorly correlated
+12.09%
More